Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Jun 23 | 2025ADA 2025 Key Press Releases (June 23) Purchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics Jun 23 | 2025Lilly ADA 2025 Investor Event; Efsitora Alfa QW Insulin Ph3 DataPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucagon, Other, Topics Jun 22 | 2025Novo ADA 2025 Investor Event and Full REDEFINE 1 and 2 ResultsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery, Other, Topics Jun 22 | 2025Beta Bionics Investor Event at ADA 2025Purchase Blast$599
Posted in: Allogeneic, Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics Jun 22 | 2025ADA 2025 Key Press Releases (June 21) Purchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Topics Jun 21 | 2025ADA 2025 Key Press Releases (June 20) Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jun 19 | 2025Zealand Topline Dapiglutide Data; Scholar Rock Ph2 Combination Trial Results; Mineralys Ph2 Topline Data in CKD; Biomea Preclinical Oral GLP-1RA Data Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Other, Topics Jun 17 | 2025FDA Commissioner Comments on T1DM at BIO Conference; Lilly Acquires Verve Therapeutics; Metsera Ph1/2 Amylin Trial; Medtronic Invests in India; Allurion Shares Data at ASMBS Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jun 16 | 2025Lilly Expands Zepbound SDVs; Ph1 Lilly Amylin Results; D&D Ph2 Obesity Data; MBX Submits IND for Obesity Asset; June CHMP Agenda Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jun 16 | 2025Obesity Spotlight: Regeneron’s Obesity Strategy Continues to EvolvePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics Jun 12 | 2025Novo Advances Amycretin to Ph3; Medtronic Diabetes Reclaims MiniMed Name; Vertex Layoffs After Failed T1DM Program Purchase Blast
$599
Posted in: GLP-1RA, Other, Topics Jun 11 | 2025Novo Signs Two Obesity Drug Development Partnerships; Lilly Enters Research Collaboration for Muscle Preservation Drug Discovery; Lilly Takes Stance Against Compounders Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Jun 10 | 2025Tandem to Integrate with Abbott’s Glucose-Ketone Sensor; Insulet iOS App Integrates with Dexcom; Ypsomed and CamDiab Expand mylife Loop iOS; BI/Echosens Expand Partnership in MASH; Altimmune Initiates New Ph2 Study in ALD Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jun 09 | 2025Metsera Topline Ph1 Amylin Data; Merck Topline Oral PCSK9i Ph3 Data; Novo Initiates New Ph3 Cagrisema Trial; Alnylam’s Amvuttra Receives EC Approval Purchase Blast
$599
Posted in: GLP-1RA, Other, Topics Jun 06 | 2025Omada Releases IPO Pricing; EMA Concludes New Semaglutide Side Effect Purchase Blast
$599
Posted in: GLP-1RA, Other, SGLT2i, Topics Jun 05 | 2025Ascletis Initiates Ph2 Obesity Study; Bayer Ph2 Finerenone + Empagliflozin CKD Results Purchase Blast
$599
Posted in: GLP-1RA, Other, Topics Jun 04 | 2025Welldoc Supports Launch of New Lilly Health App; NodThera Initiates Ph2 Study of NT-0796; Virta Claims Cost Savings for Obesity Programs Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jun 03 | 2025Lilly Enters Licensing Agreement for Long-Acting Therapies in CVRM; Hims & Hers Reduces Workforce; AstraZeneca Initiates Ph3 Oral PCSK9i Program Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jun 02 | 2025Regeneron Enters In-Licensing Agreement for Dual Agonist in Obesity and Announces Interim Ph2 Obesity Data; Nxera Achieves Milestone in Lilly Collaboration; TIXiMed Completes Ph1 Study for TIX100; Arrowhead Doses First Patients in Ph1/2a Obesity StudyPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i, Topics Jun 02 | 2025Obesity Spotlight: If Pfizer Can't Beat 'Em, Should It Join Them?Purchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
